文献速递肝肾功能剂量调整抗菌药物管理

头孢他啶-阿维巴坦肾功能剂量调整在碳青霉烯耐药革兰阴性菌感染中的临床疗效:观察性研究的系统评价与荟萃分析

Clinical efficacy of renal dosing adjustments of ceftazidime-avibactam in patients affected by carbapenem-resistant Gram-negative infections: A systematic review and meta-analysis of observational studies.
PubMed 文献 · Br J Clin Pharmacol · 2022-11-22

荟萃分析纳入7项偏倚风险中等的研究,显示肾功能剂量调整与更高的死亡风险相关(OR 1.79;95%CI 1.18-2.72)。

要点

  • 肾功能剂量调整的头孢他啶-阿维巴坦与碳青霉烯耐药革兰阴性菌感染患者死亡风险升高相关(OR 1.79;95%CI 1.18-2.72)。
  • 该结论基于7项偏倚风险中等观察性研究的荟萃分析,不能排除基线情况相关的残余混杂。
  • 需更大样本的前瞻性研究进一步明确该临床问题。

核心结论

  • 头孢他啶-阿维巴坦肾功能剂量调整似乎与碳青霉烯耐药革兰阴性菌感染患者更高的死亡风险相关。
  • 但不能排除与基线状况相关的残余混杂因素。
  • 需要更大样本的前瞻性研究来最终解决这一未满足的临床需求。

研究设计与样本

  • 纳入比较推荐肾功能剂量调整与全剂量头孢他啶-阿维巴坦治疗碳青霉烯耐药革兰阴性菌感染的随机对照试验或观察性研究。
  • 共筛选1794篇文章,纳入11项观察性研究(1项前瞻性、10项回顾性)。
  • 采用ROBINS-I工具独立评估观察性研究质量。
  • 荟萃分析仅纳入偏倚风险低或中等且对混杂因素进行调整的研究。

主要发现

  • 11项纳入研究中4项存在严重或极严重偏倚风险,其余7项为中等偏倚风险并纳入荟萃分析。
  • 肾功能剂量调整的头孢他啶-阿维巴坦与更高的死亡风险相关(OR 1.79;95%CI 1.18-2.72)。

关键数值与推荐

  • 主要结局为死亡率。
  • 肾功能剂量调整组较全剂量组死亡风险 OR 1.79(95%CI 1.18-2.72)。

临床怎么用

  • 临床对碳青霉烯耐药革兰阴性菌感染患者进行头孢他啶-阿维巴坦肾功能剂量调整时,应警惕可能增加的死亡风险。
  • 该证据来自观察性研究且存在残余混杂,临床决策需结合患者基线状况个体化评估。

局限性

  • 纳入研究均为观察性研究(1项前瞻性、10项回顾性),存在残余混杂可能。
  • 4项研究存在严重或极严重偏倚风险,仅7项中等偏倚风险研究进入荟萃分析。
  • 作者指出不能排除与基线状况相关的残余混杂因素。
  • 需要更大样本的前瞻性研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aim of this study is to assess clinical efficacy of ceftazidime-avibactam for the management of carbapenem-resistant Gram-negative infections in renal patients receiving recommended dosing adjustments compared to those treated with scheduled full-dose. METHODS: Two authors independently searched PubMed-MEDLINE and Scopus database from inception to 31 December 2021, to retrieve randomized controlled trials or observational studies comparing clinical efficacy of ceftazidime-avibactam in patients affected by carbapenem-resistant Gram-negative infections receiving recommended renal dosing adjustments compared to those treated with scheduled full-dose. Data were independently extracted by the 2 authors, and the quality of included studies was independently assessed according to ROBINS-I tool for observational studies. Mortality rate was selected as primary outcome. Meta-analysis was conducted by including only studies at low or moderate risk of bias providing adjustment for confounders. RESULTS: In total, 1794 articles were screened, and 11 observational studies (1 prospective and 10 retrospective) were included. Serious or critical risk of bias was found in 4 studies, while the other 7 were classified at moderate risk of bias and included in the meta-analysis. Renal dosing adjustments of ceftazidime-avibactam were associated with higher risk of mortality (odds ratio 1.79; 95% confidence interval 1.18-2.72). CONCLUSION: Renal dosing adjustment of ceftazidime-avibactam seems to be associated with a higher risk of mortality in patients affected by carbapenem-resistant Gram-negative infections. However, residual confounder associated with baseline conditions cannot be excluded. Further prospective studies including larger samples are warranted to definitively address this unmet clinical need.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Gatti M, Fornaro G, Viale P, et al. Clinical efficacy of renal dosing adjustments of ceftazidime-avibactam in patients affected by carbapenem-resistant Gram-negative infections: A systematic review and meta-analysis of observational studies. Br J Clin Pharmacol. 2022. PMID: 36337045. doi:10.1111/bcp.15586

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。